Q-VD-OPH Inhibitor Peptide


There are currently no images for Q-VD-OPH Inhibitor (NBP2-29391).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Func, In vitro

Order Details

Q-VD-OPH Inhibitor Peptide Summary

Q-VD-OPH is a cell permeable caspase peptide inhibitor. Caspase inhibitors irreversibly bind to the catalytic site of caspase proteases and inhibit apoptosis. Caspase inhibitors may be broad spectrum, inhibiting multiple caspases, or may preferentially inhibit particular caspases. Z-VAD-FMK, BOC-D-FMK, and Q-VD-OPH are examples of broad spectrum or pan caspase inhibitors. In contrast Z-DEVD-FMK preferentially inhibits caspases 3 and 7, Z-IETD-FMK preferentially inhibits caspase 8, Z-LEHD-FMK preferentiailly inhibits caspase 9. Z-FA-FMK is considered to be a negative control for FMK based caspase inhibitors.
Details of Functionality
Mass Spec: M+1=514.1
Chromatography: TLC:Rf: 0.4 Single Spot, EtOAC:6, ACOH:0.1
H NMR: All functional groups are present
Q-Val-Asp(non-omethylated)-OPH, also known as Q-VD(non-omethylated)-OPH. Molecular Weight: 513


Application Notes
Q-VD-OPH is a novel, irreversible, pan caspase inhibitor specifically designed for in vivo and in vitro research. Q-VD-OPH is widely cited in the literature, and researchers should refer to the literature for additional information about the various species that Q-VD-OPH has been used for.For in vitro applications, Q-VD-OPH is typically used at final working concentration of 10-100 uM. The variability depends on model system, including cell type, culture, properties, and type of apoptosis induction treatments. Each researcher should empirically establish optimal working concentrations for their in vitro model system.
For in vivo applications, the recommended dose of Q-VD-OPh is 20 mg/kg. The caspase inhibitor is administered IP in 80-100% DMSO. Doses of up to 120 mg/kg have been used in mice without toxic effects (Melnikov and Vyacheslav, 2002; Patil and Sharma, 2004). Each researcher should empirically establish optimal doses for their animal model system. Use in functional reported in scientific literature (PMID: 24068677)
Read Publications using
NBP2-29391 in the following applications:

  • 1 publication
  • WB
    1 publication

Reactivity Notes

Human reactivity reported in scientific literature (PMID: 24068677)

Packaging, Storage & Formulations

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Reconstitution Instructions
Form : Off-white Solid: Make a stock solution of 10 mM in high purity DMSO (>99.9%). Add 195 uL DMSO to 1 mg of the pan caspase inhibitor (Q-VD-OPH peptide) to make a 10 mM stock solution.


Members of the caspase family play key roles in apoptosis and inflammation. The OPH trap of Q-VD-OPH has superior potency, cell permeability, minimal toxicity, and provides an alternative to the fluoromethylketone (FMK) family of inhibitors. Like the FMK caspase inhibitors (reviewed in Thornberry and Lazebnik, 1998; Gregoli and Bondurant, 1999; Schrantz et al., 1999), Q-VD-OPH binds to the catalytic site of caspases proteases, and inhibits caspase-mediated apoptosis by preventing caspase activity. Users should consult the literature for additional information regarding applications for Q-VD-OPH (Caserta et al., 2003; Melnikov et al, 2002; Patil and Sharma, 2004)


This product is for research use only and is not approved for use in humans or in clinical diagnosis. Inhibitors are guaranteed for 1 year from date of receipt.

Publications for Q-VD-OPH Inhibitor (NBP2-29391)(8)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: Func, WB.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 8 of 8.
Publications using NBP2-29391 Applications Species
Green SE, Luczak MW, Morse JL et al. Uptake, p53 Pathway Activation, and Cytotoxic Responses for Co(II) and Ni(II) in Human Lung Cells: Implications for Carcinogenicity. Toxicol Sci 2013 Dec [PMID: 24068677] (Func, Human) Func Human
Brenner D, Golks A, Becker M et al. Caspase-cleaved HPK1 induces CD95L-independent activation-induced cell death in T and B lymphocytes. Blood. 2007 Dec 1 [PMID: 17712048] (Mouse)

Inhibition of apoptosis (primary mouse T cells), Fig. 2 D,E. Q-VD-OPH was used at 20uM to 80uM.
Arnold R, Frey CR, Muller W et al. Sustained JNK signaling by proteolytically processed HPK1 mediates IL-3 independent survival during monocytic differentiation. Cell Death Differ. 2007 Mar [PMID: 17024227]

Inhibition of caspase activity with Q-VD-OPH reduced monocyte differentiation in primary mouse progenitor cells. Q-VD-OPH was used at 5 um.
Gurfinkel DM, Chow S, Hurren R et al. Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. Apoptosis. 2006 Sep [PMID: 16820960]

Inhibition of apoptosis (Asiatic acid-treated PPC-1 prostate cells), Q-VD-OPH was used at 10 and 100 um.
Ekert PG, Jabbour AM, Manoharan A et al. Cell death provoked by loss of interleukin-3 signaling is independent of Bad, Bim, and PI3 kinase, but depends in part on Puma. Blood. 2006 Sep 1 [PMID: 16705087]

Inhibition of caspase activity (IL-3-dependent mouse cell lines), Fig. 2B. Q-VD-Z-OPH was used at 10mM and 100uM.
Patil K, Sharma SC. Broad spectrum caspase inhibitor rescues retinal ganglion cells after ischemia. Neuroreport. 2004 Apr 29 [PMID: 15076719]
Caserta TM, Smith AN, Gultice AD et al. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 2003 Aug [PMID: 12815277] (WB)

Inhibitors cited [inhibition of Actinomycin D or TGF beta induced apoptosis in WEHI 231 mouse cells, human Jurkat, or rat HRP-1 (trophoblast) cells]: 1. BOC-D-FMK (IMI-2311): Fig 1 (gel analysis of DNA laddering) 2. Z-VAD-FMK (IMI-2310): Fig 1 (gel analys
Melnikov VY, Faubel S, Siegmund B et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest. 2002 Oct [PMID: 12393844]

This publication cites OPH-001, a first generation QV-D-OPH compound. OPH-001 was synthesized as methylated Q-VD(OMe)-OPH, and then reformulated into non-methylated Q-VD-OPH, a white solid (IMI-2309). Q-VD-OPH was overall superior to OPH-001, performing b

Reviews for Q-VD-OPH Inhibitor (NBP2-29391) (0)

There are no reviews for Q-VD-OPH Inhibitor (NBP2-29391). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
  • 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen

FAQs for Q-VD-OPH Inhibitor (NBP2-29391) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Q-VD-OPH Products

Q-VD-OPH NBP2-29391

Blogs on Q-VD-OPH

There are no specific blogs for Q-VD-OPH, but you can read our latest blog posts.

Contact Information

Product PDFs

Review this Product

Be the first to review our Q-VD-OPH Inhibitor Peptide and receive a gift card or discount.